scholarly journals Virtual screen for repurposing approved and experimental drugs for candidate inhibitors of EBOLA virus infection

F1000Research ◽  
2015 ◽  
Vol 4 ◽  
pp. 34 ◽  
Author(s):  
Veljko Veljkovic ◽  
Philippe M. Loiseau ◽  
Bruno Figadere ◽  
Sanja Glisic ◽  
Nevena Veljkovic ◽  
...  
Keyword(s):  
Virtual Screening ◽  
Virus Infection ◽  
Ebola Virus ◽  
Virus Disease ◽  
Virtual Screen ◽  
Experimental Drugs ◽  
Theoretical Criterion ◽  
Approved Drugs ◽  
Molecular Libraries ◽  
Ebola Virus Infection

The ongoing Ebola virus epidemic has presented numerous challenges with respect to control and treatment because there are no approved drugs or vaccines for the Ebola virus disease (EVD). Herein is proposed simple theoretical criterion for fast virtual screening of molecular libraries for candidate inhibitors of Ebola virus infection. We performed a repurposing screen of 6438 drugs from DrugBank using this criterion and selected 267 approved and 382 experimental drugs as candidates for treatment of EVD including 15 anti-malarial drugs and 32 antibiotics. An open source Web server allowing screening of molecular libraries for candidate drugs for treatment of EVD was also established.

scholarly journals Virtual screen for repurposing approved and experimental drugs for candidate inhibitors of EBOLA virus infection

F1000Research ◽  
2015 ◽  
Vol 4 ◽  
pp. 34 ◽  
Author(s):  
Veljko Veljkovic ◽  
Philippe M. Loiseau ◽  
Bruno Figadere ◽  
Sanja Glisic ◽  
Nevena Veljkovic ◽  
...  
Keyword(s):  
Virtual Screening ◽  
Virus Infection ◽  
Ebola Virus ◽  
Virus Disease ◽  
Virtual Screen ◽  
Experimental Drugs ◽  
Theoretical Criterion ◽  
Approved Drugs ◽  
Molecular Libraries ◽  
Ebola Virus Infection

The ongoing Ebola virus epidemic has presented numerous challenges with respect to control and treatment because there are no approved drugs or vaccines for the Ebola virus disease (EVD). Herein is proposed simple theoretical criterion for fast virtual screening of molecular libraries for candidate inhibitors of Ebola virus infection. We performed a repurposing screen of 6438 drugs from DrugBank using this criterion and selected 267 approved and 382 experimental drugs as candidates for treatment of EVD including 15 anti-malarial drugs and 32 antibiotics. An open source Web server allowing screening of molecular libraries for candidate drugs for treatment of EVD was also established.

scholarly journals In silico analysis suggests repurposing of ibuprofen for prevention and treatment of EBOLA virus disease

F1000Research ◽  
2015 ◽  
Vol 4 ◽  
pp. 104 ◽  
Author(s):  
Veljko Veljkovic ◽  
Marco Goeijenbier ◽  
Sanja Glisic ◽  
Nevena Veljkovic ◽  
Vladimir R. Perovic ◽  
...  
Keyword(s):  
Ebola Virus ◽  
Virus Disease ◽  
In Silico Analysis ◽  
Ebola Virus Disease ◽  
Therapeutic Approaches ◽  
Experimental Drugs ◽  
Theoretical Criterion ◽  
Prevention And Treatment ◽  
Molecular Libraries ◽  
Ebola Virus Infection

The large 2014/2015 Ebola virus outbreak in West Africa points out the urgent need to develop new preventive and therapeutic approaches that are effective against Ebola viruses and  can be rapidly utilized. Recently, a simple theoretical criterion for the virtual screening of molecular libraries for candidate inhibitors of Ebola virus infection was proposed. Using this method the ‘drug space’ was screened and 267 approved and 382 experimental drugs as candidates for treatment of the Ebola virus disease (EVD) have been selected. Detailed analysis of these drugs revealed the non-steroidal anti-inflammatory drug ibuprofen as an inexpensive, widely accessible and minimally toxic candidate for prevention and treatment of EVD. Furthermore, the molecular mechanism underlying this possible protective effect of ibuprofen against EVD is suggested in this article.

scholarly journals Seroprevalence of Ebola virus infection in Bombali District, Sierra Leone

2017 ◽  
Author(s):  
Nadege Goumkwa Mafopa ◽  
Gianluca Russo ◽  
Raoul Emeric Guetiya Wadoum ◽  
Emmanuel Iwerima ◽  
Vincent Batwala ◽  
...  
Keyword(s):  
Immune Response ◽  
Virus Infection ◽  
West Africa ◽  
Sierra Leone ◽  
Ebola Virus ◽  
Virus Disease ◽  
Asymptomatic Infection ◽  
Ebola Virus Disease ◽  
Efficient Immune Response ◽  
Ebola Virus Infection

A serosurvey of anti-Ebola Zaire virus nucleoprotein IgG prevalence was carried out among Ebola virus disease survivors and their Community Contacts in Bombali District, Sierra Leone. Our data suggest that the specie of Ebola virus (Zaire) responsible of the 2013-2016 epidemic in West Africa may cause mild or asymptomatic infection in a proportion of cases, possibly due to an efficient immune response.

scholarly journals Ebola Virus Ribonucleic Acid Detection in Semen More Than Two Years After Resolution of Acute Ebola Virus Infection

2017 ◽  
Vol 4 (3) ◽  
Author(s):  
William A Fischer ◽  
Jerry Brown ◽  
David Alain Wohl ◽  
Amy James Loftis ◽  
Sam Tozay ◽  
...  
Keyword(s):  
Virus Infection ◽  
Ribonucleic Acid ◽  
Ebola Virus ◽  
Infectious Virus ◽  
Virus Disease ◽  
Viral Rna ◽  
Ebola Virus Disease ◽  
Positive Specimen ◽  
Ebola Virus Infection

Abstract Among 149 men who survived Ebola virus disease (EVD) and donated semen 260–1016 days after EVD onset, Ebola virus (EBOV) ribonucleic acid (RNA) was detected in 13 (9%). Of 137 men who donated semen 2 years after EVD onset, 11 (8%) had an EBOV RNA-positive specimen. The mechanism underlying the persistence of EBOV RNA in semen is unclear, and it is unclear whether the detection of viral RNA represents the presence of infectious virus.

scholarly journals Addressing Therapeutic Options for Ebola Virus Infection in Current and Future Outbreaks

2015 ◽  
Vol 59 (10) ◽  
pp. 5892-5902 ◽  
Author(s):  
Azizul Haque ◽  
Didier Hober ◽  
Joel Blondiaux
Keyword(s):  
Virus Infection ◽  
Ebola Virus ◽  
Therapeutic Agent ◽  
Cell Types ◽  
Rapid Evaluation ◽  
Hemorrhagic Disease ◽  
Treatment And Prevention ◽  
Approved Drugs ◽  
Ebola Virus Infection

ABSTRACTEbola virus can cause severe hemorrhagic disease with high fatality rates. Currently, no specific therapeutic agent or vaccine has been approved for treatment and prevention of Ebola virus infection of humans. Although the number of Ebola cases has fallen in the last few weeks, multiple outbreaks of Ebola virus infection and the likelihood of future exposure highlight the need for development and rapid evaluation of pre- and postexposure treatments. Here, we briefly review the existing and future options for anti-Ebola therapy, based on the data coming from rare clinical reports, studies on animals, and results fromin vitromodels. We also project the mechanistic hypotheses of several potential drugs against Ebola virus, including small-molecule-based drugs, which are under development and being tested in animal models orin vitrousing various cell types. Our paper discusses strategies toward identifying and testing anti-Ebola virus properties of known and medically approved drugs, especially those that can limit the pathological inflammatory response in Ebola patients and thereby provide protection from mortality. We underline the importance of developing combinational therapy for better treatment outcomes for Ebola patients.

scholarly journals A THEORETICAL STUDY ON FRACTIONAL EBOLA HEMORRHAGIC FEVER MODEL

Fractals ◽  
2021 ◽  
Author(s):  
SHAHER MOMANI ◽  
R. P. CHAUHAN ◽  
SUNIL KUMAR ◽  
SAMIR HADID
Keyword(s):  
Virus Infection ◽  
Ebola Virus ◽  
Virus Disease ◽  
Numerical Technique ◽  
Disease Model ◽  
Hemorrhagic Fever ◽  
Health Concern ◽  
Ebola Hemorrhagic Fever ◽  
Conformable Derivatives ◽  
Ebola Virus Infection

The Ebola virus infection (EVI), generally known as Ebola hemorrhagic fever, is a major health concern. The occasional outbreaks of virus occur primarily in certain parts of Africa. Many researches have been devoted to the study of the Ebola virus disease. In this paper, we have taken susceptible-infected-recovered-deceased-environment (SIRDP) system to investigate the dynamics of Ebola virus infection. We adopted fractional operators for a better illustration of model dynamics and memory effects. Initially, the Ebola disease model is modified with Caputo–Fabrizio arbitrary operator in Caputo sense (CFC) and we employed the fixed-point results for the existence and uniqueness of the solution of the fractional system. Further, we adopted the arbitrary fractional conformable and [Formula: see text]-conformable derivatives to the alternative representation of the model. For the numerical approximation of the system, we show a numerical technique based on the fundamental theorem of fractional calculus for CFC derivative and a numerical scheme called the Adams–Moulton for conformable derivatives. Finally, for the validation of theoretical results, the numerical simulations are displayed.

scholarly journals Involvement of Surfactant Protein D in Ebola Virus Infection Enhancement via Glycoprotein Interaction

Viruses ◽  
2018 ◽  
Vol 11 (1) ◽  
pp. 15 ◽  
Author(s):  
Anne-Laure Favier ◽  
Olivier Reynard ◽  
Evelyne Gout ◽  
Martin van Eijk ◽  
Henk P. Haagsman ◽  
...  
Keyword(s):  
Virus Infection ◽  
Ebola Virus ◽  
Virus Disease ◽  
Specific Interaction ◽  
Surfactant Protein ◽  
Immune Defense ◽  
Innate Immune ◽  
Surfactant Protein D ◽  
Viral Spread ◽  
Ebola Virus Infection

Since the largest 2014–2016 Ebola virus disease outbreak in West Africa, understanding of Ebola virus infection has improved, notably the involvement of innate immune mediators. Amongst them, collectins are important players in the antiviral innate immune defense. A screening of Ebola glycoprotein (GP)-collectins interactions revealed the specific interaction of human surfactant protein D (hSP-D), a lectin expressed in lung and liver, two compartments where Ebola was found in vivo. Further analyses have demonstrated an involvement of hSP-D in the enhancement of virus infection in several in vitro models. Similar effects were observed for porcine SP-D (pSP-D). In addition, both hSP-D and pSP-D interacted with Reston virus (RESTV) GP and enhanced pseudoviral infection in pulmonary cells. Thus, our study reveals a novel partner of Ebola GP that may participate to enhance viral spread.

Sign in / Sign up

Export Citation Format

Share Document